NL-OMON31863已完成不适用
A phase I, open-label, randomized crossover trial in 24 healthy subjects to investigate the effect of steady-state esomeprazole on the pharmacokinetics of a single dose of telaprevir. - Open-label, crossover of a single dose of telaprevir.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Male or female, aged between 18-55 years of age (extremes included).
- •Females, postmenopausal for at least 2 years, or posthysterectomy or post-tubal ligation.
- •Non-smoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months before study screening.
- •A body mass index of 18 to 30 kg/m^2 (extremes included)
排除标准
- •Clinical significant abnormalities at screening
研究者
相似试验
已完成
不适用
A Phase I, open label, randomized, crossover trial in healthy subjects to investigate the pharmacokinetic interaction between didanosine and TMC114, coadministered with low-dose ritonavir, at steady-state.human immunodeficiency virus (aids)10021460NL-OMON29874Tibotec Pharmaceuticals18
进行中（未招募）
不适用
AHIV-1 infectionMedDRA version: 14.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004159-38-BEJanssen R&D Ireland
进行中（未招募）
1 期
A study to assess the food effect and how fast JNJ-53718678 reaches the blood stream of healthy adult subjects after being dosed with 250-mg as an oral solid concept compared with suspension; and the effect of storage conditions on how long the drug stays and acts in the body after administration of JNJ-53718678Respiratory Syncytial VirusMedDRA version: 20.0Level: HLTClassification code 10038717Term: Respiratory syncytial viral infectionsSystem Organ Class: 100000004862EUCTR2020-000369-18-BEJanssen Sciences Ireland Unlimited Company (UC)84
进行中（未招募）
1 期
A Study to Evaluate the Relative Bioavailability of Tezacaftor/Ivacaftor GranulesMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000689-40-Outside-EU/EEAVertex Pharmaceuticals Incorporated16
未知
1 期
A Phase 1, Food Effect Study of TAK-385 Final FormulatioJPRN-jRCT2080223218TAKEDA PHARMACEUTICAL COMPANY LTD.35